Oncology

Biopharmaceutical company partners with NIH to develop oncology compound

Published in Gene Therapy Weekly, December 25th, 2003

Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) has agreed to a collaborative development program with the National Institutes of Health (NIH). The terms of the development program will be governed by a Collaborative Research and Development Agreement (CRADA) that is in the final stages of approval at the NIH.

The development program will center on the recombinant immunotoxin SS1P. Enzon and the NCI plan to initially develop SS1P in pancreatic and ovarian carcinomas. Phase 2 trials are set to start in the second half of 2004.

This compound is currently in phase 1 clinical development at the U.S. National Cancer Institute (NCI) under the supervision of Dr....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-12-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry